Share Price and Basic Stock Data
Last Updated: January 2, 2026, 12:50 pm
| PEG Ratio | -0.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Asarfi Hospital Ltd operates in the Hospitals & Medical Services industry, with a current market price of ₹188 and a market capitalization of ₹370 Cr. The company has demonstrated a robust growth trajectory in its revenue, with reported sales rising from ₹43 Cr in March 2020 to ₹116 Cr in March 2025. For the trailing twelve months (TTM), sales stood at ₹147 Cr, reflecting a strong upward trend. Quarterly sales figures also indicate consistent growth, with ₹20.05 Cr in December 2023 increasing to ₹44.85 Cr by September 2025. This growth is indicative of the company’s ability to capitalize on increasing healthcare demand, especially in the post-pandemic era, aligning with broader industry trends that reflect a shift towards heightened healthcare spending across India. The company’s annual operating profit margin (OPM) remained stable at around 20% for the last two fiscal years, showcasing effective management of operational efficiencies.
Profitability and Efficiency Metrics
Asarfi Hospital Ltd’s profitability metrics highlight a mixed performance over the years. The net profit for March 2025 was reported at ₹11 Cr, up from ₹3 Cr in March 2020. However, the net profit margin showed fluctuations, standing at 8.77% for March 2025, compared to 4.93% in March 2024. The operating profit margin (OPM) consistently hovered around 20%, demonstrating effective cost management despite increasing expenses, which rose from ₹37 Cr in March 2020 to ₹93 Cr in March 2025. The interest coverage ratio (ICR) was reported at 7.61x, indicating a strong ability to meet interest obligations. However, the cash conversion cycle (CCC) has been negative at -16 days in March 2025, suggesting efficient management of working capital. This efficiency, coupled with a return on equity (ROE) of 14.1%, positions the company favorably against typical sector standards, which often see ROE figures in lower ranges.
Balance Sheet Strength and Financial Ratios
Asarfi Hospital Ltd’s balance sheet reflects a growing financial strength, with total assets increasing from ₹28 Cr in March 2020 to ₹164 Cr in March 2025. The company’s reserves have also seen substantial growth, recorded at ₹62 Cr as of March 2025, up from ₹12 Cr in March 2020. Borrowings have risen to ₹49 Cr, which, while indicative of increased leverage, results in a long-term debt to equity ratio of 0.41, suggesting a manageable level of debt. The price to book value (P/BV) ratio stood at 2.01x, which is aligned with industry norms, indicating that the stock is trading at a fair valuation relative to its book value. The current ratio of 1.43x indicates adequate liquidity to cover short-term liabilities, while a quick ratio of 1.37x further affirms this liquidity position, positioning the company well to handle unforeseen financial challenges.
Shareholding Pattern and Investor Confidence
The shareholding structure of Asarfi Hospital Ltd showcases a strong promoter backing, with promoters holding 61.17% of the equity as of September 2025. This significant stake can be viewed positively by investors, as it indicates a strong commitment from the founding members. Institutional involvement remains minimal, with Foreign Institutional Investors (FIIs) holding just 0.05% and Domestic Institutional Investors (DIIs) at 2.18%. Public holding is significant at 36.59%, reflecting a diverse shareholder base. The number of shareholders has varied, with a notable increase from 706 in September 2023 to 1,167 by September 2025, suggesting growing investor interest. This increase in public participation may enhance liquidity and support the stock price, although the limited institutional participation may pose a risk in terms of stock volatility and overall market perception.
Outlook, Risks, and Final Insight
Looking ahead, Asarfi Hospital Ltd is well-positioned to capitalize on the growing demand for healthcare services in India. However, the company faces several risks, including rising operational costs and potential regulatory changes in the healthcare sector that could impact profitability. Additionally, the increasing debt levels may pose a challenge if not managed prudently. The company’s ability to sustain its growth trajectory will depend on maintaining operational efficiencies and managing its capital structure effectively. If Asarfi Hospital can leverage its strong promoter backing and improve institutional participation, it may enhance investor confidence and support its stock performance. Conversely, failure to address rising costs and leverage effectively could hinder growth in a competitive healthcare landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 9.44 Cr. | 21.8 | 28.7/9.80 | 20.1 | 23.4 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 370 Cr. | 188 | 221/72.9 | 26.3 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 39,260 Cr. | 1,921 | 2,372/1,257 | 46.2 | 199 | 0.23 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 253 Cr. | 122 | 141/55.0 | 378 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 13,294.33 Cr | 563.20 | 117.65 | 74.20 | 0.06% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 20.05 | 24.04 | 30.86 | 32.89 | 33.89 | 35.66 | 44.85 |
| Expenses | 16.04 | 20.05 | 24.06 | 25.90 | 28.64 | 28.63 | 35.94 |
| Operating Profit | 4.01 | 3.99 | 6.80 | 6.99 | 5.25 | 7.03 | 8.91 |
| OPM % | 20.00% | 16.60% | 22.03% | 21.25% | 15.49% | 19.71% | 19.87% |
| Other Income | 1.20 | -0.41 | 1.13 | 0.89 | 4.87 | 1.42 | 0.80 |
| Interest | 0.60 | 0.76 | 0.76 | 1.18 | 1.35 | 1.22 | 1.07 |
| Depreciation | 3.25 | 3.49 | 3.18 | 3.04 | 3.23 | 2.96 | 2.88 |
| Profit before tax | 1.36 | -0.67 | 3.99 | 3.66 | 5.54 | 4.27 | 5.76 |
| Tax % | 102.94% | -76.12% | 27.07% | 25.41% | 30.87% | 25.29% | 25.17% |
| Net Profit | -0.05 | -0.16 | 2.90 | 2.72 | 3.83 | 3.20 | 4.30 |
| EPS in Rs | -0.03 | -0.08 | 1.47 | 1.38 | 1.95 | 1.63 | 2.19 |
Last Updated: December 28, 2025, 2:04 am
Below is a detailed analysis of the quarterly data for Asarfi Hospital Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 44.85 Cr.. The value appears strong and on an upward trend. It has increased from 35.66 Cr. (Jun 2025) to 44.85 Cr., marking an increase of 9.19 Cr..
- For Expenses, as of Sep 2025, the value is 35.94 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.63 Cr. (Jun 2025) to 35.94 Cr., marking an increase of 7.31 Cr..
- For Operating Profit, as of Sep 2025, the value is 8.91 Cr.. The value appears strong and on an upward trend. It has increased from 7.03 Cr. (Jun 2025) to 8.91 Cr., marking an increase of 1.88 Cr..
- For OPM %, as of Sep 2025, the value is 19.87%. The value appears strong and on an upward trend. It has increased from 19.71% (Jun 2025) to 19.87%, marking an increase of 0.16%.
- For Other Income, as of Sep 2025, the value is 0.80 Cr.. The value appears to be declining and may need further review. It has decreased from 1.42 Cr. (Jun 2025) to 0.80 Cr., marking a decrease of 0.62 Cr..
- For Interest, as of Sep 2025, the value is 1.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.22 Cr. (Jun 2025) to 1.07 Cr., marking a decrease of 0.15 Cr..
- For Depreciation, as of Sep 2025, the value is 2.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.96 Cr. (Jun 2025) to 2.88 Cr., marking a decrease of 0.08 Cr..
- For Profit before tax, as of Sep 2025, the value is 5.76 Cr.. The value appears strong and on an upward trend. It has increased from 4.27 Cr. (Jun 2025) to 5.76 Cr., marking an increase of 1.49 Cr..
- For Tax %, as of Sep 2025, the value is 25.17%. The value appears to be improving (decreasing) as expected. It has decreased from 25.29% (Jun 2025) to 25.17%, marking a decrease of 0.12%.
- For Net Profit, as of Sep 2025, the value is 4.30 Cr.. The value appears strong and on an upward trend. It has increased from 3.20 Cr. (Jun 2025) to 4.30 Cr., marking an increase of 1.10 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.19. The value appears strong and on an upward trend. It has increased from 1.63 (Jun 2025) to 2.19, marking an increase of 0.56.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:11 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 43 | 54 | 65 | 69 | 81 | 116 | 147 |
| Expenses | 37 | 46 | 54 | 55 | 65 | 93 | 119 |
| Operating Profit | 6 | 8 | 11 | 14 | 16 | 24 | 28 |
| OPM % | 15% | 15% | 17% | 20% | 20% | 20% | 19% |
| Other Income | 0 | 0 | 1 | 2 | 2 | 8 | 8 |
| Interest | 1 | 1 | 1 | 1 | 3 | 4 | 5 |
| Depreciation | 2 | 3 | 3 | 4 | 9 | 13 | 12 |
| Profit before tax | 4 | 5 | 8 | 11 | 6 | 15 | 19 |
| Tax % | 27% | 26% | 26% | 26% | 33% | 25% | |
| Net Profit | 3 | 4 | 6 | 8 | 4 | 11 | 14 |
| EPS in Rs | 21.48 | 28.83 | 46.79 | 5.53 | 2.14 | 5.58 | 7.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.33% | 50.00% | 33.33% | -50.00% | 175.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.67% | -16.67% | -83.33% | 225.00% |
Asarfi Hospital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: July 25, 2025, 1:50 pm
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 14 | 20 | 20 |
| Reserves | 12 | 16 | 21 | 27 | 51 | 62 |
| Borrowings | 5 | 7 | 12 | 17 | 32 | 49 |
| Other Liabilities | 9 | 13 | 28 | 34 | 52 | 34 |
| Total Liabilities | 28 | 37 | 63 | 93 | 154 | 164 |
| Fixed Assets | 18 | 22 | 31 | 39 | 94 | 101 |
| CWIP | 0 | 2 | 9 | 18 | 0 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 9 | 13 | 22 | 37 | 60 | 61 |
| Total Assets | 28 | 37 | 63 | 93 | 154 | 164 |
Below is a detailed analysis of the balance sheet data for Asarfi Hospital Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2024) to 62.00 Cr., marking an increase of 11.00 Cr..
- For Borrowings, as of Mar 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 32.00 Cr. (Mar 2024) to 49.00 Cr., marking an increase of 17.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 34.00 Cr.. The value appears to be improving (decreasing). It has decreased from 52.00 Cr. (Mar 2024) to 34.00 Cr., marking a decrease of 18.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 164.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 154.00 Cr. (Mar 2024) to 164.00 Cr., marking an increase of 10.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2024) to 101.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 164.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Mar 2024) to 164.00 Cr., marking an increase of 10.00 Cr..
Notably, the Reserves (62.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | 1.00 | -1.00 | -3.00 | -16.00 | -25.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 20 | 14 | 30 | 90 | 109 | 125 |
| Inventory Days | 23 | 13 | 16 | 26 | 32 | 30 |
| Days Payable | 156 | 23 | 34 | 91 | 445 | 171 |
| Cash Conversion Cycle | -113 | 5 | 11 | 25 | -304 | -16 |
| Working Capital Days | -10 | -38 | -36 | 18 | 3 | 50 |
| ROCE % | 25% | 29% | 26% | 11% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.37 | 2.31 |
| Diluted EPS (Rs.) | 5.37 | 2.31 |
| Cash EPS (Rs.) | 11.82 | 6.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 41.16 | 35.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 41.16 | 35.78 |
| Revenue From Operations / Share (Rs.) | 61.27 | 42.89 |
| PBDIT / Share (Rs.) | 15.79 | 9.01 |
| PBIT / Share (Rs.) | 9.35 | 4.54 |
| PBT / Share (Rs.) | 7.27 | 3.17 |
| Net Profit / Share (Rs.) | 5.37 | 2.11 |
| NP After MI And SOA / Share (Rs.) | 5.37 | 2.11 |
| PBDIT Margin (%) | 25.76 | 20.99 |
| PBIT Margin (%) | 15.25 | 10.58 |
| PBT Margin (%) | 11.86 | 7.39 |
| Net Profit Margin (%) | 8.77 | 4.93 |
| NP After MI And SOA Margin (%) | 8.77 | 4.93 |
| Return on Networth / Equity (%) | 13.05 | 5.91 |
| Return on Capital Employeed (%) | 14.97 | 7.93 |
| Return On Assets (%) | 6.45 | 2.70 |
| Long Term Debt / Equity (X) | 0.41 | 0.28 |
| Total Debt / Equity (X) | 0.59 | 0.45 |
| Asset Turnover Ratio (%) | 0.75 | 0.00 |
| Current Ratio (X) | 1.43 | 1.13 |
| Quick Ratio (X) | 1.37 | 1.08 |
| Inventory Turnover Ratio (X) | 59.15 | 0.00 |
| Interest Coverage Ratio (X) | 7.61 | 6.58 |
| Interest Coverage Ratio (Post Tax) (X) | 3.59 | 2.55 |
| Enterprise Value (Cr.) | 210.28 | 142.87 |
| EV / Net Operating Revenue (X) | 1.74 | 1.69 |
| EV / EBITDA (X) | 6.77 | 8.06 |
| MarketCap / Net Operating Revenue (X) | 1.35 | 1.52 |
| Price / BV (X) | 2.01 | 1.83 |
| Price / Net Operating Revenue (X) | 1.35 | 1.52 |
| EarningsYield | 0.06 | 0.03 |
After reviewing the key financial ratios for Asarfi Hospital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 5.37, marking an increase of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 5.37, marking an increase of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 11.82, marking an increase of 5.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 41.16. It has increased from 35.78 (Mar 24) to 41.16, marking an increase of 5.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 41.16. It has increased from 35.78 (Mar 24) to 41.16, marking an increase of 5.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.27. It has increased from 42.89 (Mar 24) to 61.27, marking an increase of 18.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.79. This value is within the healthy range. It has increased from 9.01 (Mar 24) to 15.79, marking an increase of 6.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is 9.35. This value is within the healthy range. It has increased from 4.54 (Mar 24) to 9.35, marking an increase of 4.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 7.27. This value is within the healthy range. It has increased from 3.17 (Mar 24) to 7.27, marking an increase of 4.10.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.11 (Mar 24) to 5.37, marking an increase of 3.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.11 (Mar 24) to 5.37, marking an increase of 3.26.
- For PBDIT Margin (%), as of Mar 25, the value is 25.76. This value is within the healthy range. It has increased from 20.99 (Mar 24) to 25.76, marking an increase of 4.77.
- For PBIT Margin (%), as of Mar 25, the value is 15.25. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 15.25, marking an increase of 4.67.
- For PBT Margin (%), as of Mar 25, the value is 11.86. This value is within the healthy range. It has increased from 7.39 (Mar 24) to 11.86, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 8.77, marking an increase of 3.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 8.77, marking an increase of 3.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.05. This value is below the healthy minimum of 15. It has increased from 5.91 (Mar 24) to 13.05, marking an increase of 7.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.97. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 14.97, marking an increase of 7.04.
- For Return On Assets (%), as of Mar 25, the value is 6.45. This value is within the healthy range. It has increased from 2.70 (Mar 24) to 6.45, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.41. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.41, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 0.59, marking an increase of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.00 (Mar 24) to 0.75, marking an increase of 0.75.
- For Current Ratio (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 1.5. It has increased from 1.13 (Mar 24) to 1.43, marking an increase of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 1.37, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 59.15. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 59.15, marking an increase of 59.15.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.61. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 7.61, marking an increase of 1.03.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.59. This value is within the healthy range. It has increased from 2.55 (Mar 24) to 3.59, marking an increase of 1.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 210.28. It has increased from 142.87 (Mar 24) to 210.28, marking an increase of 67.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has increased from 1.69 (Mar 24) to 1.74, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 6.77. This value is within the healthy range. It has decreased from 8.06 (Mar 24) to 6.77, marking a decrease of 1.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.52 (Mar 24) to 1.35, marking a decrease of 0.17.
- For Price / BV (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.01, marking an increase of 0.18.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.52 (Mar 24) to 1.35, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Asarfi Hospital Ltd:
- Net Profit Margin: 8.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.97% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.05% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.3 (Industry average Stock P/E: 117.65)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 4th Floor, Asarfi Hospital, Dhanbad Jharkand 828130 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Udai Pratap Singh | Managing Director |
| Mrs. Madhuri Singh | Executive Director |
| Mr. Gopal Singh | Executive Director |
| Dr. Sukanti Kumar Das | Non Executive Director |
| Mrs. Rajkumari Sharma | Independent Director |
| Mr. Amit Kumar Barnwal | Independent Director |
FAQ
What is the intrinsic value of Asarfi Hospital Ltd?
Asarfi Hospital Ltd's intrinsic value (as of 04 January 2026) is ₹136.77 which is 27.25% lower the current market price of ₹188.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹370 Cr. market cap, FY2025-2026 high/low of ₹221/72.9, reserves of ₹62 Cr, and liabilities of ₹164 Cr.
What is the Market Cap of Asarfi Hospital Ltd?
The Market Cap of Asarfi Hospital Ltd is 370 Cr..
What is the current Stock Price of Asarfi Hospital Ltd as on 04 January 2026?
The current stock price of Asarfi Hospital Ltd as on 04 January 2026 is ₹188.
What is the High / Low of Asarfi Hospital Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Asarfi Hospital Ltd stocks is ₹221/72.9.
What is the Stock P/E of Asarfi Hospital Ltd?
The Stock P/E of Asarfi Hospital Ltd is 26.3.
What is the Book Value of Asarfi Hospital Ltd?
The Book Value of Asarfi Hospital Ltd is 45.2.
What is the Dividend Yield of Asarfi Hospital Ltd?
The Dividend Yield of Asarfi Hospital Ltd is 0.00 %.
What is the ROCE of Asarfi Hospital Ltd?
The ROCE of Asarfi Hospital Ltd is 15.8 %.
What is the ROE of Asarfi Hospital Ltd?
The ROE of Asarfi Hospital Ltd is 14.1 %.
What is the Face Value of Asarfi Hospital Ltd?
The Face Value of Asarfi Hospital Ltd is 10.0.